Monday, December 23, 2024
     
Advertisement
  1. You Are At:
  2. News
  3. Video
  4. News Video
  5. COVAXIN shows interim efficacy of 81% in phase 3 clinical trials: Bharat Biotech

News Videos

Updated on: March 03, 2021 18:30 IST

COVAXIN shows interim efficacy of 81% in phase 3 clinical trials: Bharat Biotech

India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.

Next Video

Latest Videos

Aaj Ki Baat→

Aap Ki Adalat→

Sports→

Oh My God→

Kurukshetra→

Entertainment→

Advertisement

Recommended Video

Advertisement

Top News

Advertisement

Latest News

Advertisement